2017 Final Results

EKF Diagnostics Holdings announces its final results for the year ended 31 December 2017.

For full results please download the PDF .

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
N+1 Singer Alex Price / Alex Laughton-Scott	00 44 20 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF to highlighta new Glycated Albumin assay kit at AACC 2018

EKF Diagnostics, the global in vitro diagnostics company, announces that on Booth #3880 at the AACC 2018 Clinical Lab Expo it will be highlighting a new Stanbio Chemistry Glycated Albumin (GA) assay kit and its newly FDA cleared DiaSpect Tm hemoglobin point of care analyzer. Located in Chicago, IL, from July 31^st to August 2^nd, AACC is the world’s largest exposition for clinical laboratory products and services.

EKF at AACC - Chicago 2018

EKF POC HbA1c analyzer demonstrates excellent performance in international evaluation study

Quo-Lab meets strict international quality targets – confirming it fit for purpose for diabetes testing

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results.

Quo Lab takes off in Italy

In a drive to improve management of diabetes, a campaign was launched in Italy to raise awareness introduction of EKF's Quo Lab system in all hospitals of the the Lazio region.